10 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $2M | -$259M | 87.1% | -18599.8% | -$214M | — | $29M |
| 2024 | $7M | -$158M | 97.2% | -2778.9% | -$160M | — | $28M |
| 2023 | $7M | -$141M | 95.6% | -2245.3% | -$109M | — | $35M |
| 2022 | $2M | -$112M | 95.8% | -4889.0% | -$106M | — | $29M |
| 2021 | $5M | -$71M | 97.8% | -1531.8% | -$62M | — | $39M |
| 2020 | $7M | — | 97.3% | -854.1% | -$42M | — | $44M |
| 2019 | $4M | — | 97.2% | -1540.2% | -$47M | — | $11M |
| 2018 | $10M | — | 92.7% | -1640.1% | -$76M | — | $24M |
| 2017 | $13M | — | 94.5% | -953.7% | -$102M | — | $40M |
| 2016 | $7M | — | 76.4% | -1958.7% | -$116M | — | $42M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $15000 | -$79M | 0.0% | -562900.0% | -$67M | — | $36M |
| Dec '25 | $121000 | -$81M | 0.0% | -72027.3% | -$65M | — | $29M |
| Sep '25 | $0 | -$67M | — | — | -$49M | — | $36M |
| Jun '25 | $730000 | -$57M | 0.0% | -8747.5% | -$45M | — | $23M |
| Mar '25 | $695000 | -$54M | 0.0% | -9027.2% | -$55M | — | $17M |
| Dec '24 | $1M | -$47M | 0.0% | -4768.3% | -$33M | — | $28M |
| Sep '24 | $3M | -$42M | 0.0% | -1633.5% | -$56M | — | $36M |
| Jun '24 | $2M | -$36M | 0.0% | -1854.2% | -$30M | — | $43M |
| Mar '24 | $156000 | -$33M | 0.0% | -26030.8% | -$41M | — | $115M |
| Dec '23 | $4M | — | 0.0% | -1152.9% | -$33M | — | $35M |
| Sep '23 | $2M | — | 0.0% | -2718.5% | -$19M | — | $21M |
| Jun '23 | $268000 | — | 0.0% | -12389.9% | -$28M | — | $28M |
| Mar '23 | $967000 | — | 0.0% | -3357.9% | -$29M | — | $54M |
| Dec '22 | $2M | — | 0.0% | -1728.8% | -$22M | — | $29M |
| Sep '22 | $407000 | — | 0.0% | -6804.9% | -$36M | — | $19M |
| Jun '22 | $163000 | — | 0.0% | -22328.8% | -$23M | — | $28M |
| Mar '22 | $174000 | — | 0.0% | -13366.1% | -$25M | — | $25M |
| Dec '21 | $334000 | — | 0.0% | -6089.8% | -$15M | — | $39M |
| Sep '21 | $153000 | — | 0.0% | -13610.5% | -$17M | — | $72M |
| Jun '21 | $3M | — | 0.0% | -386.2% | -$12M | — | $43M |
How the market has priced CLDX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Celldex Therapeutics, Inc.'s revenue has declined 26.9% per year. These are computed facts, not advice.
As of FY2025, Celldex Therapeutics, Inc. reported — of total debt against $29M of cash.
In FY2025, gross margin was 87.1%, operating margin -18599.8%, and net margin -16748.0%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.